ES2084621T3 - Proteina biologicamente activa modificada. - Google Patents

Proteina biologicamente activa modificada.

Info

Publication number
ES2084621T3
ES2084621T3 ES90112690T ES90112690T ES2084621T3 ES 2084621 T3 ES2084621 T3 ES 2084621T3 ES 90112690 T ES90112690 T ES 90112690T ES 90112690 T ES90112690 T ES 90112690T ES 2084621 T3 ES2084621 T3 ES 2084621T3
Authority
ES
Spain
Prior art keywords
biologically active
modified protein
active modified
active protein
consisting essentially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90112690T
Other languages
English (en)
Inventor
Yutaka Mizushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP1310056A external-priority patent/JP2679852B2/ja
Application filed by Asahi Glass Co Ltd, Seikagaku Corp filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of ES2084621T3 publication Critical patent/ES2084621T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA PROTEINA MODIFICADA, BIOLOGICAMENTE ACTIVA, QUE SE COMPONE ESENCIALMENTE DE UNA PROTEINA BIOLOGICAMENTE ACTIVA ENLAZADA CON LECITINA MEDIANTE UN FIJADOR QUIMICO.
ES90112690T 1989-07-06 1990-07-03 Proteina biologicamente activa modificada. Expired - Lifetime ES2084621T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17437189 1989-07-06
JP1310056A JP2679852B2 (ja) 1989-11-29 1989-11-29 経口及び局所投与用生物活性蛋白組成物

Publications (1)

Publication Number Publication Date
ES2084621T3 true ES2084621T3 (es) 1996-05-16

Family

ID=26496004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90112690T Expired - Lifetime ES2084621T3 (es) 1989-07-06 1990-07-03 Proteina biologicamente activa modificada.

Country Status (8)

Country Link
US (3) US5109118A (es)
EP (1) EP0406804B1 (es)
AT (1) ATE133200T1 (es)
AU (1) AU647027B2 (es)
CA (1) CA2020439C (es)
DE (1) DE69024862T2 (es)
DK (1) DK0406804T3 (es)
ES (1) ES2084621T3 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
ATE244570T1 (de) 1993-09-09 2003-07-15 Lorus Therapeutics Inc Immunmodulierende zusammensetzungen aus galle
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
NZ302638A (en) 1995-03-16 2001-04-27 Imutec Pharma Inc Immunomodulating composition from bile for the treatment of immune system disorders
JP3599347B2 (ja) * 1995-09-06 2004-12-08 協和醗酵工業株式会社 脂質代謝改善剤
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6800607B2 (en) * 2000-02-29 2004-10-05 Ltt Bio-Pharma Co., Ltd. Modified BDNF
WO2004096843A1 (ja) 2003-04-30 2004-11-11 Shigekazu Nakatsugawa 消化器官吸収性ポリペプチド
JP4958556B2 (ja) * 2004-10-12 2012-06-20 株式会社Ｌｔｔバイオファーマ レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
KR100752990B1 (ko) * 2006-08-02 2007-08-30 주식회사 대웅 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
US8802681B2 (en) 2008-10-17 2014-08-12 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
BR112012005124B1 (pt) 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
ES2584634T3 (es) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
AU2012225337B2 (en) 2011-03-09 2016-04-28 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
US12599578B2 (en) 2021-03-09 2026-04-14 Ensysce Biosciences Inc. Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3476770D1 (en) * 1983-04-11 1989-03-23 Meito Sangyo Kk Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
US4560599A (en) * 1984-02-13 1985-12-24 Marquette University Assembling multilayers of polymerizable surfactant on a surface of a solid material
US4957740A (en) * 1984-10-31 1990-09-18 Centerchem, Inc. Composition for preventing or alleviating skin irritation by formulations containing superoxide dismutase
WO1986004232A1 (en) * 1985-01-18 1986-07-31 Cooper-Lipotech, Inc. Liposome composition and method
JPS63135395A (ja) * 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JPS63253031A (ja) * 1987-04-09 1988-10-20 Yutaka Mizushima ス−パ−オキサイドジスムタ−ゼ結合リピツドマイクロスフエア−および該リピツドマイクロスフエア−を含有する脂肪乳剤
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
US5080833A (en) * 1987-09-21 1992-01-14 Kabushiki Kaisha Toshiba Immobilization of bioactive substance on lipid composition containing modified lipid compound
IL93925A0 (en) * 1989-03-29 1990-12-23 Alcon Lab Inc Pharmaceutical compositions containing a monoacyl phosphogylceride
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform

Also Published As

Publication number Publication date
DK0406804T3 (da) 1996-06-10
US5109118A (en) 1992-04-28
EP0406804A3 (en) 1992-04-01
CA2020439A1 (en) 1991-01-07
AU5865290A (en) 1991-01-10
EP0406804A2 (en) 1991-01-09
DE69024862T2 (de) 1996-09-05
EP0406804B1 (en) 1996-01-17
DE69024862D1 (de) 1996-02-29
AU647027B2 (en) 1994-03-17
CA2020439C (en) 1998-11-24
US5310958A (en) 1994-05-10
US5362491A (en) 1994-11-08
ATE133200T1 (de) 1996-02-15

Similar Documents

Publication Publication Date Title
ES2084621T3 (es) Proteina biologicamente activa modificada.
DE3586313D1 (de) Konjugate von pharmazeutisch nuetzlichen proteinen.
SE8000470L (sv) Vevnadsbindmedel och forfarande for dess framstellning samt bindmedlets anvendning
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
ATE241011T1 (de) Serin-reiche peptidlinker
FI91160B (fi) Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
ES2043609T3 (es) Composiciones de interleucina-2.
FI885504A0 (fi) Vaskulaera antikoagulerande proteiner, dessa koderande dna, deras framstaellningsfoerfarande och deras anvaendning.
FI885807L (fi) Puhdistetun, biologisesti aktiivisen, bakteerien avulla tuotetun rekombinanttisen ihmis- CSF-1:n tuottaminen
FI864552A0 (fi) Human-lysozym.
FI904852A0 (fi) Antikoagulantpeptider.
PT90504A (pt) Processo para a preparacao de alcoois peptidicos com actividade anticoagulante
ES536059A0 (es) Procedimiento de ligacion de sustancias biologicamente importantes
DK109590A (da) Biologisk aktivt protein
TR24383A (tr) Konsantre yuezey aktif madde granuelleri yapmaya mahsus yoentem
DK614489A (da) Peptidderivater
FI891820A7 (fi) Biologisesti aktiiviset yhdisteet
DE3869939D1 (de) Biologisch wirksame peptide.
DE3782199D1 (de) Biologisch aktive peptide tan-866.
KR870018415U (ko) 미싱의 노루발
DK661888D0 (da) Biologisk aktive molekyler
PT7986U (pt) Fixacao de protese capilar por integracao com ponto natural
KR880021166U (ko) 1회용 슬리퍼
KR880017238U (ko) 신발깔창 부착용 공기주입기
AT388624B (de) Einrichtung zur fussbetaetigung von tasteninstrumenten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 406804

Country of ref document: ES